Skip to Main Content

Paper Details

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Am Heart J
98
2018
ASCVD, CV, CV death, CV disease, Dapagliflozin, MACE, MACEs, Patients, SGLT-2, T2DM, atherosclerotic cardiovascular disease, dapagliflozin, glucose, glycosuria, heart failure, ischemic stroke, myocardial infarction, patients, sodium, sodium-glucose co-transporter-2, type 2 diabetes mellitus
Author NameAffiliation
Michael G SilvermanMassachusetts General Hospital
Deepak L BhattBrigham and Women's Hospital
Marc S SabatineBrigham and Women's Hospital
Marc S SabatineBrigham and Women's Hospital
  • 1 - 4

Datasets

Release 1.2